文献速递流行病学与生物统计医学教育与科研方法

临床试验全生命周期中的翻译与口译服务

Translation and interpreting services must be considered across the lifecycle of clinical trials.
PubMed 文献 · Trials · 2026-06-11

本文指出英语水平有限(LEP)人群在英语国家的临床试验中被不成比例地排除,主要因翻译和口译支持不足。文章论述语言支持应贯穿试验全生命周期,涵盖招募、知情同意、结局测量、干预实施、安全报告等环节,并提出系统化建议。结论强调需协调的全生命周期策略及国家层面标准、集中化服务模式和培训。

要点

  • LEP人群因翻译口译支持不足在临床试验中被不成比例排除。
  • 语言支持应覆盖临床试验全生命周期而非仅招募和知情同意阶段。
  • 需早期规划、透明预算、质量标准和研究者培训及系统级变革。

核心结论

  • 解决临床试验中的语言多样性需要协调的全生命周期策略,超越仅在招募咨询时提供翻译材料。
  • 系统级变革如明确国家统一标准、集中化服务模式和更好培训对减少不平等和增强试验结果可靠性至关重要。
  • 确保LEP人群在整个参与过程中得到支持将增强信任、改善安全并促进更具代表性的证据。

研究设计与样本

  • 本文为评论文章(commentary),非原始研究,未报告样本量或系统检索方法。

主要发现

  • LEP人群在英语国家临床试验中被不成比例排除,主要因翻译和口译支持不足。
  • 挑战包括确定需翻译的语言和材料、翻译质量保证、预算复杂性、依赖不合格口译员及不同站点服务差异。
  • 实际影响涉及招募、知情同意、结局测量、干预实施、招募与保留监测、安全报告及全程沟通。

关键数值与推荐

  • 建议早期规划、透明预算、稳健质量标准和研究者培训。
  • 建议申办方、资助方、医疗服务提供者、研究团队和研究治理组织采用更系统和公平的翻译口译方法。
  • 建议国家统一标准、集中化服务模式和更好培训等系统级变革。

临床怎么用

  • 在试验全生命周期各环节整合翻译和口译支持,而非仅招募和知情同意阶段。
  • 早期规划语言支持并透明预算,建立翻译质量标准和培训研究者。
  • 采用系统级方法如国家统一标准和集中化服务模式以减少不平等。

局限性

  • 本文为评论文章,未报告原始研究数据、样本量或系统评价方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inclusive clinical research requires that all prospective participants are provided with accessible, comprehensible information to support informed decision-making regarding trial participation. However, people with limited English proficiency (LEP) remain disproportionately excluded from trials in English-speaking countries, largely due to insufficient translation and interpretation support. This exclusion compromises equity, participant safety, and the integrity and generalisability of trial findings. MAIN BODY: This commentary highlights why language support must be considered across the entire clinical trial lifecycle, rather than limited to recruitment and consent stages. We examine challenges including identifying which languages and materials require translation; quality assurance of translations; budgeting complexities; reliance on underqualified interpreters; and variability in provision across sites. Practical implications span recruitment, informed consent, outcome measures, intervention delivery, monitoring recruitment and retention, safety reporting, and communication to participants throughout the trial. We emphasise the need for early planning, transparent budgeting, robust quality standards, and researcher training. Drawing on existing frameworks and recent evidence, we provide recommendations on how sponsors, funders, healthcare providers, research teams, and research governance organisations can move towards more systematic and equitable approaches to translation and interpretation. CONCLUSION: Addressing linguistic diversity in clinical trials requires a coordinated, lifecycle-wide strategy that goes beyond providing translated materials at the recruitment consultation. System-level changes, such as clear national standards, centralised models of provision, and better training are essential to reduce inequities and enhance the reliability of trial outcomes. Ensuring that people with LEP are supported throughout their participation will strengthen trust, improve safety, and contribute to more representative evidence for healthcare decision-making.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Roberts K, Lewis R, Iqbal G, et al. Translation and interpreting services must be considered across the lifecycle of clinical trials. Trials. 2026. PMID: 42277920. doi:10.1186/s13063-026-09840-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。